EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A predictive serum miRNA signature impacts diffuse large B‐cell lymphoma cell viability via inhibition of EGLN1 and TXNRD1 regulators of ferroptosis

Giulia Regazzo, Giulia Vari, Francesco Marchesi iD, Ana Belén Díaz Méndez, Marta Di Giuliani, Andrea Sacconi, Francesca Palombi, Valentina Lulli, Frauke Goeman, Mariangela Novello, Martina Tomassi, Elena Papa und 4 weitere

British Journal of Haematology · 2025

DOI: 10.1111/bjh.70017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Giulia Regazzo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research, Advanced Diagnostics and Technological Innovation, Translational Oncology Research Unit, IRCCS - Regina Elena National Cancer…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Ferroptosis, MicroRNAs, Thioredoxin Reductase 1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Italian Ministry of Health, Associazione Mia Neri Foundation, Cassa Sovvenzioni e Risparmio Dipendenti Banca d'Italia, Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse large B‐cell lymphoma (DLBCL) is a heterogeneous disorder. Prognostic factors include genomic alterations and cell‐of‐origin (COO) subtypes, even though they cannot fully predict treatment response. MicroRNAs (miRNAs) deregulated in patient tumours and blood are promising non‐invasive biomarkers. Several circulating miRNAs were found to be correlated with progression‐free survival (PFS), independently of other prognosticators. However, miRNA signatures, rather than individual miRNAs, represent more reliable biomarkers and a better mirror of the disease. In this study, we identified circulating miRNAs differentially expressed between R‐CHOP refractory and responding subjects by small‐RNA sequencing on serum from 33 DLBCL patients. Among the identified miRNAs, the combined expression of three of them improved the predictive performance and was correlated with PFS. Two out of three miRNAs, miR‐421 and miR‐324‐5p, were also differentially expressed in tumour tissues based on treatment response. Overexpressing these miRNAs reduced cell proliferation, viability and resistance to R‐CHOP in the germinal centre B‐like COO subtype. EGLN1 and TXNRD1 , regulators of oxygen metabolism and redox homeostasis, were identified as miRNA targets and the silencing or inhibition of these genes impaired cell viability and induced ferroptosis. These results support the application of a two‐miRNA signature and its targets for novel combined therapeutic interventions in DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseFerroptosisMicroRNAsThioredoxin Reductase 1RNA, NeoplasmNeoplasm ProteinsHumansMaleFemaleCell SurvivalMiddle AgedDoxorubicinVincristineAntineoplastic Combined Chemotherapy ProtocolsRituximabCyclophosphamideAgedPrednisoneGene Expression Regulation, NeoplasticCell Line, TumorBiomarkers, TumorAdultPrognosis

Stichwörter der Autor:innen

circulating microRNAsdiffuse large B‐cell lymphomaferroptosis regulatorspredictive biomarkers

Substanzen

MicroRNAsThioredoxin Reductase 1TXNRD1 protein, humanDoxorubicinVincristineRituximabCyclophosphamidePrednisoneR-CHOP protocolBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Research, Advanced Diagnostics and Technological Innovation, Translational Oncology Research Unit, IRCCS - Regina Elena National Cancer Institute, Rome, Italy.
  • Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
  • Hematology Unit, IRCCS - Regina Elena National Cancer Institute, Rome, Italy.
  • Biostatistics and Bioinformatics Unit, Clinical Trial Center, IRCCS - Regina Elena National Cancer Institute, Rome, Italy.
  • Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
  • SAFU Unit, IRCCS - Regina Elena National Cancer Institute, Rome, Italy.

ORCID-Profile: Francesco Marchesi, Maria Giulia Rizzo

Förderung

  • Italian Ministry of Health
  • Associazione Mia Neri Foundation, Cassa Sovvenzioni e Risparmio Dipendenti Banca d'Italia
  • Ministero della Salute

Zitieren

APA

Regazzo, G., Vari, G., Marchesi, F., Díaz Méndez, A. B., Di Giuliani, M., Sacconi, A., Palombi, F., Lulli, V., Goeman, F., Novello, M., Tomassi, M., Papa, E., Bertoni, F., Hohaus, S., Mengarelli, A., & Rizzo, M. G. (2025). A predictive serum miRNA signature impacts diffuse large B‐cell lymphoma cell viability via inhibition of EGLN1 and TXNRD1 regulators of ferroptosis. British Journal of Haematology. https://doi.org/10.1111/bjh.70017

Vancouver

Regazzo G, Vari G, Marchesi F, Díaz Méndez AB, Di Giuliani M, Sacconi A, et al. A predictive serum miRNA signature impacts diffuse large B‐cell lymphoma cell viability via inhibition of EGLN1 and TXNRD1 regulators of ferroptosis. British Journal of Haematology. 2025. doi:10.1111/bjh.70017

BibTeX
@article{Regazzo2025,
  author = {Regazzo, Giulia and Vari, Giulia and Marchesi, Francesco and Díaz Méndez, Ana Belén and Di Giuliani, Marta and Sacconi, Andrea and Palombi, Francesca and Lulli, Valentina and Goeman, Frauke and Novello, Mariangela and Tomassi, Martina and Papa, Elena and Bertoni, Francesco and Hohaus, Stefan and Mengarelli, Andrea and Rizzo, Maria Giulia},
  title = {A predictive serum miRNA signature impacts diffuse large B‐cell lymphoma cell viability via inhibition of EGLN1 and TXNRD1 regulators of ferroptosis},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.70017}
}
Kostenlos starten →